These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 26001728)
21. Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? Segelmark M; Persson B; Hellmark T; Wieslander J Clin Exp Immunol; 1997 Apr; 108(1):167-74. PubMed ID: 9097926 [TBL] [Abstract][Full Text] [Related]
22. Manipulation of thrombin exosite I, by ligand-directed covalent modification. Yegneswaran S; Tiefenbrunn TK; Fernández JA; Dawson PE J Thromb Haemost; 2007 Oct; 5(10):2062-9. PubMed ID: 17883702 [TBL] [Abstract][Full Text] [Related]
23. Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis. Nzeusseu Toukap A; Delporte C; Noyon C; Franck T; Rousseau A; Serteyn D; Raes M; Vanhaeverbeek M; Moguilevsky N; Nève J; Vanhamme L; Durez P; Van Antwerpen P; Zouaoui Boudjeltia K Free Radic Res; 2014 Apr; 48(4):461-5. PubMed ID: 24460011 [TBL] [Abstract][Full Text] [Related]
24. High-resolution atomic force microscopy visualization of metalloproteins and their complexes. Barinov NA; Vlasova II; Sokolov AV; Kostevich VA; Dubrovin EV; Klinov DV Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2862-2868. PubMed ID: 30251674 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin. Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441 [TBL] [Abstract][Full Text] [Related]
26. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Zacharski LR; Memoli VA; Morain WD; Schlaeppi JM; Rousseau SM Thromb Haemost; 1995 May; 73(5):793-7. PubMed ID: 7482405 [TBL] [Abstract][Full Text] [Related]
27. Effect of chronic periodontitis on oxidative status in patients with rheumatoid arthritis. Sezer U; Erciyas K; Ustün K; Pehlivan Y; Şenyurt SZ; Aksoy N; Tarakçıoğlu M; Taysı S; Onat AM J Periodontol; 2013 Jun; 84(6):785-92. PubMed ID: 22799756 [TBL] [Abstract][Full Text] [Related]
28. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Villoutreix BO; Dahlbäck B Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335 [TBL] [Abstract][Full Text] [Related]
29. Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. Louro MO; Cocho JA; Mera A; Tutor JC J Trace Elem Med Biol; 2000 Oct; 14(3):174-8. PubMed ID: 11130855 [TBL] [Abstract][Full Text] [Related]
30. Copper levels in patients with rheumatoid arthritis. Strecker D; Mierzecki A; Radomska K Ann Agric Environ Med; 2013; 20(2):312-6. PubMed ID: 23772583 [TBL] [Abstract][Full Text] [Related]
31. Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental arthritis. Odobasic D; Yang Y; Muljadi RC; O'Sullivan KM; Kao W; Smith M; Morand EF; Holdsworth SR Arthritis Rheumatol; 2014 Apr; 66(4):907-17. PubMed ID: 24757143 [TBL] [Abstract][Full Text] [Related]
32. Ferroxidase and ascorbate oxidase activities of caeruloplasmin in synovial fluid from rheumatoid patients. Blake DR; Blann A; Bacon PA; Farr M; Gutteridge JM; Halliwell B Clin Sci (Lond); 1983 May; 64(5):551-3. PubMed ID: 6403279 [TBL] [Abstract][Full Text] [Related]
33. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Berckmans RJ; Nieuwland R; Tak PP; Böing AN; Romijn FP; Kraan MC; Breedveld FC; Hack CE; Sturk A Arthritis Rheum; 2002 Nov; 46(11):2857-66. PubMed ID: 12428225 [TBL] [Abstract][Full Text] [Related]
35. The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Griffin SV; Chapman PT; Lianos EA; Lockwood CM Kidney Int; 1999 Mar; 55(3):917-25. PubMed ID: 10027928 [TBL] [Abstract][Full Text] [Related]
36. Crystal structure of thrombin in complex with fibrinogen gamma' peptide. Pineda AO; Chen ZW; Marino F; Mathews FS; Mosesson MW; Di Cera E Biophys Chem; 2007 Feb; 125(2-3):556-9. PubMed ID: 16962697 [TBL] [Abstract][Full Text] [Related]
37. The effects of exosite occupancy on the substrate specificity of thrombin. Ng NM; Quinsey NS; Matthews AY; Kaiserman D; Wijeyewickrema LC; Bird PI; Thompson PE; Pike RN Arch Biochem Biophys; 2009 Sep; 489(1-2):48-54. PubMed ID: 19638274 [TBL] [Abstract][Full Text] [Related]
38. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442 [TBL] [Abstract][Full Text] [Related]
39. Study of interaction of ceruloplasmin, lactoferrin, and myeloperoxidase by photon correlation spectroscopy. Sokolov AV; Prozorovskii VN; Vasilyev VB Biochemistry (Mosc); 2009 Nov; 74(11):1225-7. PubMed ID: 19916937 [TBL] [Abstract][Full Text] [Related]
40. The protective effect of normal and pathological (Wilson disease) ceruloplasmins on human erythrocytes. Saenko EL; Skorobogat'ko OV; Yaropolov AI Biochem Int; 1990; 20(3):463-9. PubMed ID: 2161227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]